Inlexistertib

DCC-3116 · Deciphera Pharmaceuticals, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Inlexistertib, covering 2026-04-08 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors [Phase 1]